Hackensack Meridian Health

Bernhard and Hackensack Meridian Health Forge a Transformative 30-Year Energy Partnership, HMH Hospitals to be Largest Renewable Energy Not-for-Profit Healthcare Provider in the United States

Retrieved on: 
금요일, 4월 19, 2024
Education, Climate change, Forum, Risk, Hospital, State, Hackensack Meridian Health, HMH, Bed, Health care, Partnership, Electricity, SHC, Carbon footprint, Carbon, Hackensack University Medical Center, Environment, Cloud computing, Physician, Workforce, Bayshore Medical Center, Community, Joint Commission, Energy, Renewable energy

"This partnership marks a significant milestone in sustainable healthcare practices and underscores Hackensack Meridian Health's unwavering commitment to energy resilience and environmental sustainability," said Robert C. Garrett, FACHE, CEO of Hackensack Meridian Health.

Key Points: 
  • "This partnership marks a significant milestone in sustainable healthcare practices and underscores Hackensack Meridian Health's unwavering commitment to energy resilience and environmental sustainability," said Robert C. Garrett, FACHE, CEO of Hackensack Meridian Health.
  • Bernhard, with more than 100 years of energy and infrastructure project experience, stands as the largest turnkey Energy-as-a-Service solutions provider in North America.
  • Additionally, Hackensack Meridian Health CEO Robert C. Garrett is Chair of the World Economic Forum's (Forum) Health and Healthcare Governor's Community.
  • This partnership between Bernhard and Hackensack Meridian Health signifies a commitment to sustainable practices, operational efficiency, and the advancement of healthcare infrastructure.

Hackensack Meridian Hackensack University Medical Center Among First Hospitals in the World To Acquire and Use the Da Vinci 5 Multiport Robotic Surgical System

Retrieved on: 
화요일, 4월 9, 2024
Hackensack University Medical Center, Vibration, Hysterectomy, Health, Surgeon, Hackensack Meridian Health, Professor, Education, Patient, Hospital, Trauma, Research, Artificial intelligence, Force, Insufflation, Workflow, Patient safety, Fatigue, Intuitive Surgical, Intuition, Engineering, Dentistry

HACKENSACK, N.J., April 9, 2024 /PRNewswire/ -- Hackensack Meridian Hackensack University Medical Center, a center of excellence and an international leader in robotic-assisted surgery, was selected to be one of only 14 centers in the world, and the only in New Jersey, New York and Connecticut, to acquire the Intuitive Surgical da Vinci 5 multiport surgical system. With more than 10,000 times the computing power and the first-of-its-kind force-sensing technology, the da Vinci 5 is the most advanced surgical technology available.

Key Points: 
  • The Hackensack University Medical Center team performed the first procedures ever using the new system to treat the four patients on Monday, April 1, 2024.
  • Da Vinci 5 builds on Intuitive's da Vinci Xi's highly functional design, which surgeons and care teams around the world have used in more than 7 million procedures to date.
  • Expanded computing power and advanced data capabilities: Da Vinci 5 has more than 10,000 times the computing power of da Vinci Xi.
  • Robotic surgery innovations and "firsts" include:
    Robotic surgery began at Hackensack University Medical Center in 2000 with two da Vinci™ robots.

Hackensack Meridian Health Breaks Ground On First In the Nation Health & Wellness Center At A Transit Hub, Bringing Comprehensive, Convenient and Easily Accessible Healthcare To New Jersey Transit's Metropark Station

Retrieved on: 
금요일, 3월 8, 2024
County, Hackensack Meridian Health, Restaurant, Phlebotomy, Investment, Physician, Health, Biophysical environment, Transport, Work, HMH, NJ Transit, Growth, Sport, Transit-oriented development, Certification, Administration, JLL, New Jersey General Assembly, LEED, Metropark station, Ambulatory care, Patient, Health equity, Ayushman Bharat Yojana, Travel

I am pleased to join Hackensack Meridian Health today and applaud their continued work to provide vital health care to the people of New Jersey."

Key Points: 
  • I am pleased to join Hackensack Meridian Health today and applaud their continued work to provide vital health care to the people of New Jersey."
  • When it opens next year, the Hackensack Meridian Health and Wellness Center will offer more than 60,000 square feet of healthcare services just steps from the mass transit hub.
  • "Hackensack Meridian Health is committed to expanding access to quality healthcare, meeting patients where they are," said Robert C. Garrett, chief executive officer of Hackensack Meridian Health.
  • The Hackensack Meridian Health and Wellness Center at Metropark is scheduled to open in 2025.

Four Hackensack Meridian Health Hospitals First in Nation to Achieve The Joint Commission's Sustainable Healthcare Certification

Retrieved on: 
수요일, 3월 6, 2024
Certification, Hospital, Hackensack Meridian Health, Doctor of Philosophy, Weather, SHC, MD, Health, Hackensack University Medical Center, Gold, White, Carbon, Risk, Joint Commission, Climate change, Element, Patient, Cyclone, MSHA, MACP, GHG, Wildfire, Nursing

OAKBROOK TERRACE, Ill. and EDISON, N.J., March 6, 2024 /PRNewswire/ -- Four hospitals within Hackensack Meridian Health, New Jersey's largest and most integrated health network, are first in the nation to achieve The Joint Commission's Sustainable Healthcare Certification (SHC).

Key Points: 
  • OAKBROOK TERRACE, Ill. and EDISON, N.J., March 6, 2024 /PRNewswire/ -- Four hospitals within Hackensack Meridian Health, New Jersey's largest and most integrated health network, are first in the nation to achieve The Joint Commission's Sustainable Healthcare Certification (SHC).
  • "We are incredibly proud to be the first hospital network in the nation to receive The Joint Commission's Sustainable Healthcare Certification," said Robert C. Garrett, FACHE, CEO of Hackensack Meridian Health.
  • Four of its hospitals were among the first in the nation to achieve The Joint Commission's Healthcare Equity Certification in late 2023.
  • "Achieving The Joint Commission's Healthcare Equity Certification and Sustainable Healthcare Certification demonstrate Hackensack Meridian Health's leadership role and commitment toward responsible and ethical practices."

Lumeris and Hackensack Meridian Health Discuss How a Data-Driven Approach to SDOH Analytics Improve Care at HIMSS24

Retrieved on: 
화요일, 3월 5, 2024
HIMSS, Bias, Health, Doctor of Education, SDOH, Community, Social determinants of health, Hackensack Meridian Health, Organization, Patient, Acceleration, Nursing

ST. LOUIS, March 5, 2024 /PRNewswire/ -- Jean-Claude Saghbini, President of Value-based Care Enablement and Chief Technology Officer at Lumeris, the market-leading value-based care enablement company, will speak at HIMSS24 with Nicole Harris-Hollingsworth, EdD, MCHES, Vice President, Social Determinants of Health at Hackensack Meridian Health. The pair will discuss how analytics and a data-driven approach can be used to avoid selection bias and improve health outcomes for vulnerable populations.

Key Points: 
  • The pair will discuss how analytics and a data-driven approach can be used to avoid selection bias and improve health outcomes for vulnerable populations.
  • The acceleration of value-based care adoption has necessitated the use of analytics as organizations scale their efforts to more proactively and effectively provide care across populations.
  • "Our work with Hackensack Meridian Health exemplifies how the use of SDOH data and experienced partners can help organizations accomplish their goals equitably and scalably.
  • "Hackensack Meridian Health is dedicated to helping our patients experience their best health," said Nicole Harris-Hollingsworth, EdD, MCHES, Vice President, Social Determinants of Health for Hackensack Meridian Health.

The Inner Circle Acknowledges, Paul V. Sunkavalli as a Pinnacle Lifetime Member

Retrieved on: 
월요일, 2월 12, 2024
Philosophy, Mary, mother of Jesus, Hackensack Meridian Health, College, Inner circle, Chemistry, Education, Spartan Health Sciences University, Saint Mary's College, University, Patient, Family, Mount Sinai Medical Center, ADHD, Child, Trust, Biology, Spectrum, Baylor University, Physician, Hindu temple, Partnership, Nursing

MANAHAWKIN, N.J., Feb. 12, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Paul V. Sunkavalli is acknowledged as a Pinnacle Lifetime Member for his contributions to the field of Pediatrics.

Key Points: 
  • MANAHAWKIN, N.J., Feb. 12, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Paul V. Sunkavalli is acknowledged as a Pinnacle Lifetime Member for his contributions to the field of Pediatrics.
  • Dr. Sunkavalli pursued higher education at St. Mary's College where he earned a double major in biology and chemistry after transferring from Baylor University.
  • He received a Doctor of Medicine degree from Spartan Health Sciences University in St. Lucia; completed a Pediatric residency at Mount Sinai Medical Center (Jersey City Program).
  • Dr. Sunkavalli asserts that he is inspired by his entire family, including his father, Dr. Krishna Sunkavalli and his wife Dr. Anupama Sunkavalli.

The Washington, D.C. Auto Show, the Washington Area Hyundai Dealers and Hyundai Hope on Wheels Team up to Support Georgetown Lombardi and Children’s National Hospital Through “Hyundai Hands On Hope” Contest

Retrieved on: 
수요일, 1월 17, 2024
Research, Cancer, NCI, Young adult, National Cancer Institute, Walter, Washington Convention Center, Diagnosis, Adolescence, Hope, Hackensack Meridian Health, L Street Bridge, Hyundai Motor America, Washington Auto Show, Georgetown University Medical Center, MedStar Health, Health, Hyundai, Child, Hospital, Human, Ewing sarcoma, Contest, Partnership, News, Nursing, Clinical trial, Automotive industry

Drawing inspiration from Hyundai Hope on Wheels, the new contest was named “Hyundai Hands On Hope.”

Key Points: 
  • Drawing inspiration from Hyundai Hope on Wheels, the new contest was named “Hyundai Hands On Hope.”
    Six contestants will compete for a brand-new 2024 Hyundai IONIQ6 over the 44-hour contest period.
  • “Every 36 minutes a child is diagnosed with pediatric cancer” shared Kevin Reilly, President of The Washington Area Hyundai Dealers, and Vice Chair of Hyundai Hope on Wheels.
  • In 2023, Hyundai Hope on Wheels celebrated its 25th Anniversary since inception, donating over $225 million in pediatric cancer research grants.
  • A part of Georgetown University Medical Center, Georgetown Lombardi is the only comprehensive cancer center in the Washington, D.C., area.

How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

Retrieved on: 
수요일, 1월 24, 2024
Teaching hospital, Research, Anxiety, Life, Benzodiazepine, MADRS, MindMed, NEO, Diagnosis, Depression, Growth, Therapy, Disorder, Psilocybin, Hackensack Meridian Health, Safety, DSM-IV codes, Phase, PALM, GAD, Buspirone, Mental health, PD, University Hospital of Basel, Quality of life, Call-progress tone, CMPS, Patient, Generalized anxiety disorder, Food, HMH, FDA, EU4, Anticonvulsant, DMT, News, Pharmaceutical industry

PALM BEACH, Fla., Jan. 24, 2024 /PRNewswire/ -- The coming years could see a massive shift in the U.S. government's approach to regulating hallucinogenic drugs. Several biopharma companies are developing psychedelics-based treatments for various mental health conditions like Generalized Anxiety Disorder (GAD). GAD is a prevalent mental health condition characterized by excessive and persistent worry, often extending beyond specific triggers. Individuals with GAD experience heightened levels of anxiety, anticipating future events and exhibiting physical symptoms such as muscle tension and restlessness. The disorder significantly impairs daily functioning and quality of life. A report from Delveinsight said that the total market size of the Generalized Anxiety Disorder (GAD) treatment market is anticipated to experience growth during the forecast period (2032) due to the emergence of new and effective treatments, especially numerous trials developing new and innovative next-generation psychedelic treatment options. The report added: "The diagnosis of Generalized Anxiety Disorder (GAD) involves a comprehensive assessment of an individual's mental health, considering the presence of excessive and uncontrollable worry across various aspects of life for a minimum of six months. Clinicians utilize standardized psychiatric interviews and validated screening tools to evaluate the severity of anxiety symptoms, along with a thorough exploration of associated physical and psychological manifestations. Differential diagnosis is crucial to rule out other psychiatric conditions, medical disorders, or substance-related issues that may mimic GAD symptoms. The diagnostic process also entails considering the impact of anxiety on daily functioning and its persistence in the absence of identifiable stressors. A multidimensional approach aids in ensuring an accurate diagnosis and facilitates the development of an effective treatment plan tailored to the individual's needs." Active Companies active today in markets include: Cybin Inc. (NYSE: CYBN) (NEO: CYBN), COMPASS Pathways plc (NASDAQ: CMPS), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), Seelos Therapeutics, Inc. (NASDAQ: SEEL), atai Life Sciences (NASDAQ: ATAI).

Key Points: 
  • Several biopharma companies are developing psychedelics-based treatments for various mental health conditions like Generalized Anxiety Disorder (GAD).
  • It continued: "DelveInsight's analyst projects that among the total diagnosed prevalent cases of Generalized Anxiety Disorder (GAD) in 7MM approximately 53% of cases were from the US.
  • The Generalized Anxiety Disorder (GAD) market is projected to witness consistent growth throughout the forecast period (2023–2032).
  • The market size of Generalized Anxiety Disorder (GAD) in the 7MM is expected to increase, driven by better diagnosis and the launch of emerging therapies."

How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

Retrieved on: 
수요일, 1월 24, 2024
Teaching hospital, Research, Anxiety, Life, Benzodiazepine, MADRS, MindMed, NEO, Diagnosis, Depression, Growth, Therapy, Disorder, Psilocybin, Hackensack Meridian Health, Safety, DSM-IV codes, Phase, PALM, GAD, Buspirone, Mental health, PD, University Hospital of Basel, Quality of life, Call-progress tone, CMPS, Patient, Generalized anxiety disorder, Food, HMH, FDA, EU4, Anticonvulsant, DMT, News, Pharmaceutical industry

PALM BEACH, Fla., Jan. 24, 2024 /PRNewswire/ -- The coming years could see a massive shift in the U.S. government's approach to regulating hallucinogenic drugs. Several biopharma companies are developing psychedelics-based treatments for various mental health conditions like Generalized Anxiety Disorder (GAD). GAD is a prevalent mental health condition characterized by excessive and persistent worry, often extending beyond specific triggers. Individuals with GAD experience heightened levels of anxiety, anticipating future events and exhibiting physical symptoms such as muscle tension and restlessness. The disorder significantly impairs daily functioning and quality of life. A report from Delveinsight said that the total market size of the Generalized Anxiety Disorder (GAD) treatment market is anticipated to experience growth during the forecast period (2032) due to the emergence of new and effective treatments, especially numerous trials developing new and innovative next-generation psychedelic treatment options. The report added: "The diagnosis of Generalized Anxiety Disorder (GAD) involves a comprehensive assessment of an individual's mental health, considering the presence of excessive and uncontrollable worry across various aspects of life for a minimum of six months. Clinicians utilize standardized psychiatric interviews and validated screening tools to evaluate the severity of anxiety symptoms, along with a thorough exploration of associated physical and psychological manifestations. Differential diagnosis is crucial to rule out other psychiatric conditions, medical disorders, or substance-related issues that may mimic GAD symptoms. The diagnostic process also entails considering the impact of anxiety on daily functioning and its persistence in the absence of identifiable stressors. A multidimensional approach aids in ensuring an accurate diagnosis and facilitates the development of an effective treatment plan tailored to the individual's needs." Active Companies active today in markets include: Cybin Inc. (NYSE: CYBN) (NEO: CYBN), COMPASS Pathways plc (NASDAQ: CMPS), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), Seelos Therapeutics, Inc. (NASDAQ: SEEL), atai Life Sciences (NASDAQ: ATAI).

Key Points: 
  • Several biopharma companies are developing psychedelics-based treatments for various mental health conditions like Generalized Anxiety Disorder (GAD).
  • It continued: "DelveInsight's analyst projects that among the total diagnosed prevalent cases of Generalized Anxiety Disorder (GAD) in 7MM approximately 53% of cases were from the US.
  • The Generalized Anxiety Disorder (GAD) market is projected to witness consistent growth throughout the forecast period (2023–2032).
  • The market size of Generalized Anxiety Disorder (GAD) in the 7MM is expected to increase, driven by better diagnosis and the launch of emerging therapies."

Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved

Retrieved on: 
화요일, 1월 16, 2024
Patient, Depression, Hospital, Health, Hackensack University Medical Center, Mental health, Hackensack Meridian Health, News, HMH, FDA, Compass, CMPS, Nursing

The collaboration between Compass and HMH aims to improve health outcomes and improve patient and provider experiences for mental health conditions such as treatment-resistant depression.

Key Points: 
  • The collaboration between Compass and HMH aims to improve health outcomes and improve patient and provider experiences for mental health conditions such as treatment-resistant depression.
  • COMP360 is Compass’s investigational proprietary formulation of synthetic psilocybin, administered in conjunction with psychological support.
  • Hackensack Meridian Health offers a complete range of medical services, innovative research and life-enhancing care.
  • “We’re proud to collaborate with Compass Pathways, a leading biotechnology company aiming to create real change for people suffering with some of the most difficult-to-treat mental health conditions,” said Robert C. Garrett, FACHE, CEO of Hackensack Meridian Health.